Prim Care by Richards, Thomas B. et al.
Lung Cancer Screening with Low-Dose Computed Tomography 
for Primary Care Providers
Thomas B. Richards, MDa,*, Mary C. White, ScDa, and Ralph S. Caraballo, PhDb
aDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and 
Health Promotion, Centers for Disease Control and Prevention, Building 107, F-76, 4770 Buford 
Highway Northeast, Atlanta, GA 30341-3717, USA
bOffice of Smoking and Health, National Center for Chronic Disease Prevention and Health 
Promotion, Centers for Disease Control and Prevention, Building 107, F-79, 4770 Buford 
Highway Northeast, Atlanta, GA 30341-3717, USA
Abstract
This review provides an update on lung cancer screening with low-dose computed tomography 
(LDCT) and its implications for primary care providers. One of the unique features of lung cancer 
screening is the potential complexity in patient management if an LDCT scan reveals a small 
pulmonary nodule. Additional tests, consultation with multiple specialists, and follow-up 
evaluations may be needed to evaluate whether lung cancer is present. Primary care providers 
should know the resources available in their communities for lung cancer screening with LDCT 
and smoking cessation, and the key points to be addressed in informed and shared decision-
making discussions with patients.
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POPULATION MEASURES OF LUNG CANCER
Occurrence
Each year in the United States 206,000 people are told that they have lung cancer, and 
160,000 die of this disease.1 Lung cancer represents 14% of all invasive cancers diagnosed 
each year and 28% of all cancer deaths in the United States population.1 The overall 5-year 
relative survival of patients with lung cancer is less than 18%.2 More than half of lung 
cancers have distant metastasis at the time of diagnosis, and the 5-year relative survival after 
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distant metastasis is less than 5%.2 The average life expectancy of a patient with lung cancer 
is shortened by about 14 years.3
Cost
The total national cost of lung cancer care in 2010 was estimated at more than US$12 
billion, and the cost could grow to exceed $18 billion by the year 2020.4 The deductibles 
and copays incurred by individual patients with lung cancer can exceed well over $1000 per 
month.5 Lung cancer screening with low-dose computed tomography (LDCT) at the 
patient’s own expense can result in decreased intention to undergo screening and a lower 
adherence to attend an annual follow-up.6 Some health care facilities have developed 
initiatives to provide the initial examination for lung cancer screening with LDCT at no cost 
to the patient.7 National estimates of additional annual health expenditures related to lung 
cancer screening are still in the early stages, make different assumptions, and have come to 
varying conclusions.8–12 The costs of an initial LDCT examination for lung cancer 
screening have been advertised at $99 to $1000.13 The additional costs associated with 
follow-up evaluation and the treatment of abnormalities can be substantial; the 
implementation of lung cancer screening with LDCT has been estimated to increase the 
annual national health care expenditures by $1.3 to $2.0 billion if the screening rates were to 
reach 50% to 75% among those eligible for screening.11
Patterns Across Age, Sex, and Time
During the period 2005 to 2009, the incidence of lung cancer in the United States was 
highest among those aged 75 years and older, and decreased with decreasing age.14 In all 
age groups except persons younger than 44 years, incidence rates of lung cancer were higher 
among men than among women; this difference being greatest among those aged 75 years 
and older, and narrowed with decreasing age.14 In men, age-adjusted death rates for lung 
cancer increased until 1990 and then began to decrease.15,16 In women, age-adjusted death 
rates for lung cancer peaked in 2004 and have had a lower rate of decline than for men.16 
These trends in incidence and mortality are thought to reflect changes in smoking patterns 
over time.17,18
Disparities
Disparities exist in the incidence and death rates of lung cancer within the United States 
population by race, ethnicity, and geography. Among men, the incidence and death rates are 
highest among blacks than among other racial and ethnic groups.1 Among women, the 
incidence and death rates are similar between whites and blacks and highest among whites 
in comparison with other groups.1 At all ages for both men and women, Asian and Pacific 
Islanders and Hispanics have lower incidence and death rates than other groups.1 Incidence 
of lung cancer varies between states,14,19 and is highest in the South and lowest in the 
West.20 Large geographic differences have been demonstrated in incidence rates of lung 
cancer for American Indian and Alaska Native populations, with the highest rates in the 
Plains and Alaska.21 Research suggests that multiple factors may be associated with tobacco 
use, including socioeconomic status, education, cultural beliefs, and environmental 
influences.22–24 Differences in the prevalence of exposures to other carcinogens and risk 
factors may also explain some of the observed differences in incidence rates between whites 
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and blacks.25 In addition, differences in access to and the use of health care services, in 
addition to the quality of treatment, have been shown to contribute to disparities in outcomes 
of lung cancer.26,27 In a recent study, fatalistic beliefs including the concern that radiation 
exposure from a computed tomography (CT) scan could cause lung cancer and anxiety 
related to CT scans were reported to be strongly associated with a decrease in the intention 
to undergo screening among black and Hispanic adults in comparison with nonminority 
adults.28
Histology
Lung cancer refers to a group of cancers that form in the lung; different types have 
traditionally been distinguished by the differences in the morphologic appearance observed 
under a light microscope. Genetic and genomic criteria are needed to better understand and 
predict the varying biologic behavior of the different types.29 Often in public health 
statistics, nearly all lung cancer is presented as 2 categories: non–small cell carcinoma (85% 
of the total lung cancer cases) and small cell carcinoma (14%).2 Non–small cell carcinomas 
are further classified as adenocarcinoma (41% of the total lung cancer cases), squamous cell 
and transitional cell carcinoma (21%), large-cell carcinoma (3%), and non–small cell not 
otherwise specified (20%).2 Data from selected cancer registries in the 1960s and 1970s 
showed an increase in the rates of adenocarcinoma, and by the 1980s adenocarcinoma had 
become more common than squamous cell carcinoma among both men and women.30 The 
incidence of small cell lung cancer has decreased over time; whereas 73% of cases of small 
cell lung cancer were initially in men, the male-to-female ratio is now 1:1.22.31 Details on 
the histology of lung cancer are important considerations for its clinical management. For 
example, surgical resection is the primary treatment for stage I and II non–small cell lung 
cancer in patients with small surgical risk.32 By contrast, localized-stage small cell lung 
cancer is treated with concurrent chemoradiotherapy.33
ETIOLOGY
Tobacco
Cigarette smoking is the major cause of lung cancer in the United States and 
worldwide.34–36 During the period 2005 to 2009 in the United States, excluding deaths from 
second hand smoke, 84% of annual deaths from lung cancer in men and 76% in women 
were attributed to cigarette smoking.35 Only a fraction of smokers develop lung cancer in 
their lifetime and lung cancer can develop in non-smokers, indicating that other factors in 
addition to smoking play a role in its development.18,37,38 The most effective preventive 
measures are to never start smoking or to stop cigarette smoking as soon as possible. In 
2012, 18% (42 million) of United States adults aged 18 years upward were current cigarette 
smokers.39 The risk of lung cancer increases with both the duration and intensity of 
smoking,34 but the number of years smoked is a stronger predictor of lung cancer than the 
number of cigarettes smoked per day.40
Over the course of a lifetime, the risk of developing lung cancer can be 20 times or greater 
for smokers than for lifetime nonsmokers.34 Smokers who quit smoking continue to have a 
higher risk than lifetime nonsmokers of developing lung cancer, but this risk diminishes 
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over time.38,41 More than half of all adult current smokers have attempted to quit for at least 
1 day in the past year.42 Charts to demonstrate the harms of cigarette smoking have been 
developed for use by physicians to discuss these issues with patients.43 The charts show the 
10-year risks of dying of lung cancer considering age, sex, and smoking status (current 
smoker, former smoker, and lifetime nonsmoker). The charts are available online in several 
formats, and can be posted in clinic offices for easy reference or distributed among 
patients.43
Secondhand Smoke
Secondhand smoke is the term used to describe sidestream smoke (the smoke released from 
the burning end of a cigarette) and exhaled mainstream smoke (the smoke exhaled by the 
smoker). Secondhand smoke is a recognized cause of lung cancer; however, the secondhand 
smoke-attributable mortality for lung cancer is 4%.35 The increase over the background risk 
of lung cancer among nonsmokers living with a smoker has been estimated to be 20% to 
30%.35 According to data from the National Health and Nutrition Examination Survey, 
during 2007 to 2008 approximately 88 million nonsmokers aged 3 years or older in the 
United States were exposed to secondhand smoke. The prevalence of exposure was higher 
for children (aged 3–11 years) and youth (aged 12–19 years) than for adults aged 20 years or 
older.35 During 2005 to 2009 in the United States, 7330 deaths from lung cancer were 
attributed to exposure to secondhand smoke among nonsmokers.35
Radon
The US Environmental Protection Agency (EPA) publication “A Citizen’s Guide to Radon” 
is an excellent resource for any questions about radon.44 Selected highlights are as follows. 
Radon is a radioactive gas produced by the natural decay of uranium in soils, rocks, and 
water. Radon gas can seep into buildings through cracks in foundations, accumulate in 
indoor air, and thereby increase the risk of lung cancer for both smokers and nonsmokers.45 
In the United States, an estimated 1 in 15 American homes have high levels of radon. The 
EPA and the Surgeon General recommend testing all homes for radon. Test kits can be 
obtained from state radon programs, home improvement and hardware stores, and other 
sources.44,46 Radon is measured in picocuries per liter of air (pCi/L). On average, radon 
levels are 0.4 pCi/L for outdoor air and 1.3 pCi/L for indoor air. The EPA recommends 
radon mitigation to 2 pCi/L or less if indoor air levels remain at least 4 pCi/L.44 A certified 
or qualified radon contractor should design and install the radon-reduction system.44 The 
design depends on the house, but a common example is a soil-suction system to prevent 
radon from entering the home, whereby a pipe system and fans are used to draw radon gas 
from below the home and vent it to the outside.44
Occupational Exposures
Many chemical and physical agents have been demonstrated to cause lung cancer among 
working populations. Some of the most frequently mentioned occupational lung carcinogens 
include asbestos, beryllium, cadmium, chloromethyl ethers, chromium (hexavalent, hereafter 
abbreviated VI), nickel, diesel exhaust, radon, and silica.36,47 Industries with higher levels 
of exposure to lung carcinogens include mining, construction, manufacturing, agriculture, 
and certain service sectors. The number of adult workers in the United States exposed to 
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carcinogens at work has been estimated to be many millions.48 Tens of thousands of 
chemicals used in industries have never been evaluated for their carcinogenicity, and many 
of these chemicals are found in the general environment and consumer products.48 Special 
occupational standards have been established for only a relatively small number of lung 
carcinogens, including asbestos, arsenic, chromium(VI), cadmium, and formaldehyde.49 
These standards were established after lengthy regulatory proceedings that considered many 
factors in addition to the health risk, including the feasibility of controlling the exposures 
and limits in the monitoring technology.
Outdoor Air Pollution
The combustion of fossil fuels by motor vehicles and other sources releases fine particulate 
matter, diesel exhaust, and other pollutants into the atmosphere. A growing body of 
evidence links outdoor air pollution with increased rates of lung cancer in the general 
population.50,51 In 2013, the International Agency for Research on Cancer (IARC), a special 
agency of the World Health Organization, classified outdoor air pollution as carcinogenic to 
humans and found sufficient evidence to conclude that exposure to outdoor air pollution 
causes lung cancer.52 Particulate matter, a major component of outdoor air pollution, was 
evaluated separately and was also classified by the IARC as carcinogenic to humans. In 
2007, 13.6% of the general United States population resided in counties that exceeded the 
air pollution standard for fine particles, and minority groups were more likely than whites to 
live in these areas.53 In addition, an estimated 1.8 million tons of mobile sources of toxic 
emissions in the air were reported in 2005 in the United States; a Healthy People 2020 
objective is to reduce this figure to 1 million tons.54
Additional Risk Factors
Several other factors are associated with the increased risk of lung cancer. Examples include 
family history of lung cancer; chronic obstructive lung disease; fibrotic lung disorders such 
as pneumoconiosis; and human immunodeficiency virus (HIV) infection.36,55
LUNG CANCER SCREENING TESTS
Computed Tomography Lung Examinations
LDCT tests (sometimes abbreviated as low-dose CT) can be used to screen individuals at 
high risk for lung cancer. The individual lies still on a table, and the LDCT scanner rotates 
around the individual as the table passes through the center of the scanner. The entire chest 
is scanned in about 7 to 15 seconds during a single breath-hold. The scanner may include 
more than 1 source of x-rays. The x-ray sources follow a path similar to a helix or spiral as 
they rotate around the patient (some publications use helix and others use spiral; these terms 
are interchangeable). Rows of detectors are used to capture the x-ray information 
corresponding to multiple cross sections (thin slices) of the lung. Computers can create 
images from the x-ray information and assemble the images into a series of 2-dimensional 
slices of the lung at very small intervals.
Additional evaluation is needed to confirm that lung cancer is present if an LDCT scan 
reveals a pulmonary nodule.56–59 Pulmonary nodules with a low probability of cancer may 
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be followed with repeat LDCT screening over a period of time for growth-rate evaluation.13 
For nodules with a moderate probability of lung cancer, higher-dose diagnostic LDCT scans 
are often used in combination with positron emission tomography scans to evaluate the 
possibility of cancer metastasis. Biopsies may also be obtained. Depending on the results, 
patients are further evaluated for treatment.
A national consensus has not yet been developed for a standardized reporting system for 
lung cancer screening with LDCT equivalent to the Breast Imaging Reporting and Data 
System for mammography reporting.60 A Lung Reporting and Data System equivalent has 
been proposed.7
National Surveys of Practice Patterns
Recent national survey information on lung cancer screening is limited. In a national survey 
of 962 practicing primary care physicians in 2006/2007, 55% had ordered chest radiography 
for lung cancer screening and 22% had ordered LDCT scans.61,62 In the 2010 National 
Health Interview Survey, 2.5% of adults reported undergoing chest radiography in the prior 
year to check for lung cancer, and 1.3% reported undergoing chest CT to check for lung 
cancer.63
National Lung Screening Trial
The National Lung Screening Trial (NLST) was a randomized controlled trial to compare 
the effects of helical LDCT and standard chest radiography on the death rates for lung 
cancer among individuals at high risk for lung cancer in the United States.64,65 The NLST 
was conducted at 33 locations and enrolled 53,454 adults starting in 2002. Eligible 
participants were between 55 and 74 years of age at the time of randomization with a history 
of cigarette smoking of at least 30 pack-years, and former smokers if they had quit within 
the previous 15 years. Half of the participants were randomly assigned to lung cancer 
screening with LDCT, and the other half to screening with single-view posteroanterior chest 
radiography. Subjects were screened annually for 3 years. In 2011, the NLST reported a 
20% reduction in mortality from lung cancer among individuals screened by LDCT when 
compared with individuals screened by chest radiography.65 Table 1 summarizes selected 
NLST benefits and harms. The benefits of lung LDCT screening for reducing deaths from 
lung cancer was greater among older, heavier smokers who greatly exceeded the minimum 
eligibility requirements for screening than among younger, less heavy smokers closer to the 
minimum eligibility requirements.66,67 Two annual LDCT screenings resulted in a decrease 
in the number of advanced-stage cancers diagnosed and an increase in the number of early-
stage lung cancers diagnosed.68
Cancer Intervention and Surveillance Modeling Network
The Cancer Intervention and Surveillance Modeling Network (CISNET) used data from the 
NLST and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial to compare 
multiple scenarios of lung cancer screening.69 All scenarios followed a cohort of 100,000 
persons aged 45 to 90 years until death from any cause. Variations included the frequency of 
screening (annual, every 2 years, or every 3 years); age to begin screening (age 45, 50, 55, 
or 60 years); age to end screening (age 75, 80, or 85 years); minimum pack-years for 
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screening eligibility (10, 20, 30, or 40 years); and maximum years since quitting for 
screening eligibility (10, 15, 20, or 25 years). Five models, developed by investigators at 5 
different institutions, were used in the analyses, and estimates were averaged across the 5 
models. CISNET analyses of the number of deaths from lung cancer included 7.5 years of 
follow-up compared with the 6.5 years in the NLST. With the additional year, the estimated 
lung cancer–specific reduction in mortality was 14%, rather than the 20% reduction reported 
in 2011 by the NLST. Annual screening resulted in the greatest reduction in mortality (11%–
21% reduction), in comparison with biennial screening (6.5%–9.6% reduction) and triennial 
screening (≤6% reduction). The CISNET modelers concluded that the optimal balance of 
benefits and harms would be provided by starting annual screening at age 55 years, and 
ending screening at the age of 80 years for smokers with at least 30 pack-years and for 
former smokers no more than 15 years since quitting.69 The CISNET identification code for 
this scenario was A55-80-30-15. Table 2 summarizes selected benefits and harms for this 
scenario projected by CISNET.
Overdiagnosis of lung cancer is defined as the detection of indolent lung cancer that would 
not have become clinically apparent.70 Overdiagnosis is possible using lung cancer 
screening with LDCT, but estimates of the frequency have varied. The NLST Overdiagnosis 
Writing Team estimated the upper bound on the probability of overdiagnosis to be 18.5% 
(95% confidence interval 5.4%–30.6%) for cases identified by LDCT screening.70 The 
CISNET modelers estimated overdiagnosis to be present in 9.9% of all screen-detected cases 
for scenario A55-80-30-15.69
European Studies
In Europe, several randomized controlled trials are in various stages of progress.71–76 In 
general, compared with the NLST, the European trials have studied a smaller number of 
subjects and have used different screening intervals, numbers of rounds, and methods. For 
example, some of the European studies have used 3-dimensional scans in addition to 2-
dimensional scans. Moreover, volume-doubling time is being used in some European trials 
to assess change in nodule size over time between 2 scans.77 The probability that a nodule is 
malignant is low if the volume-doubling time is 400 days or more.77,78
SCREENING RECOMMENDATIONS
Task Force Recommendation
In 2013, the US Preventive Services Task Force (Task Force) recommended “annual 
screening for lung cancer with low-dose computed tomography in adults ages 55 to 80 years 
who have a 30 pack-year smoking history and currently smoke or have quit within the past 
15 years.”79,80 The Task Force also recommended that “screening should be discontinued 
once a person has not smoked for 15 years or develops a health problem that substantially 
limits life expectancy or the ability or willingness to have curative lung surgery.”79,80 
Approximately 10 million people in the United States would qualify for lung cancer 
screening with LDCT based on these NLST age and smoking criteria.63
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Many organizations in the United States updated their recommendations on lung cancer 
screening following the 2011 NLST report (Table 3).81–86 Although differences exist 
between organizations, many recommend eligibility criteria similar to those of NLST; they 
also recommend smoking cessation services or referral, and performance of screening in 
facilities with access to multispecialty expertise for follow-up management.
ORGANIZATIONAL CHARACTERISTICS THAT FACILITATE BEST 
PRACTICE
Structured Screening Program
In the section labeled “Other Considerations,” the Task Force’s 2013 recommendation 
statement encourages standardization of LDCT screening and the follow-up of abnormal 
findings, and the development of a registry to collect the data needed to enable continuous 
improvement in screening program quality over time.80 Several organizations in the United 
States have recommended that lung cancer screening and follow-up be conducted as part of 
a structured, high-volume, high-quality program including a multidisciplinary team skilled 
in the evaluation and treatment of lung cancer (Box 1).81–86 A national consensus on the 
standards for structured programs does not exist at present; depending on the elements 
required, the availability of lung cancer screening services with LDCT might be limited to 
larger, urban health care markets, where specialists are more likely to practice.87
The Lung Cancer Alliance has published a National Framework for Excellence in Lung 
Cancer Screening and Continuum of Care.88 The principles of this framework include: clear 
information on eligibility and risks and benefits; compliance with standards for best 
practices from the National Comprehensive Cancer Network and the International Early 
Lung Action Program; a multidisciplinary team for a coordinated continuum of care; 
comprehensive smoking cessation; reporting results expeditiously to patients and physicians; 
participation in outcome data collection; and providing information on how screened 
individuals can advance research.
The American College of Radiology (ACR) offers a Computed Tomography accreditation 
program that includes evaluation of personnel qualifications, equipment specifications, and 
quality control.89 A searchable list of locations with ACR CT accreditation is available on 
the ACR Web site.90 A practice guideline for radiologists is being developed by the ACR 
and the Society of Thoracic Radiology.91 The American Lung Association has 
recommended that hospitals and screening centers establish ethical policies for advertising 
and promoting lung cancer screening services with LDCT.85
Quality Control
In its “Clinician Fact Sheet,” the Task Force states that the effectiveness of lung cancer 
screening depends on accurate interpretation of LDCT images and resolving most false-
positive results without invasive procedures, in addition to limiting screening to people at 
high risk.79 Consistent quality of LDCT images is critical to identifying abnormalities and 
tracking changes in suspicious findings over time while avoiding excessive exposure.92,93 
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Quality control and accreditation programs are needed to monitor the equipment 
performance and adherence to imaging protocols.92,93 A centralized database may be helpful 
in identifying and flagging deviations from established protocols. In the NLST, quality 
assurance included a centralized review of a random sample of 1504 LDCT examinations. 
Quality defect rates ranged from 0% to 7.1%.93
Radiation Exposure and Dose
In the NLST, each LDCT resulted in an estimated effective dose of 1.5 millisievert (mSv) 
per examination.64 In a 2013 survey of 15 academic medical centers in the United States, the 
average mean effective radiation dose for LDCT screening was reported as less than 1 mSv 
at 5 centers (33%), 1 to 2 mSv at 7 centers (47%), 2 to 3 mSv at 2 centers (13%); 1 
respondent did not know the dose.91
At least 1 radiology journal no longer accepts research articles that describe radiation as 
“low dose” because improvement in LDCT technology continually decreases the amount of 
radiation exposure considered low dose.94 As an alternative, the following measures were 
suggested: volume CT dose index, dose length product, a measure of patient dimensions 
(effective diameter), and size-specific dose estimate on a per-patient basis.94
Methods are needed to track both the amount of radiation exposure during an individual 
examination and the total cumulative dose received by an individual over time.95 
Development of a multidisciplinary committee to reduce the radiation dose, repeat rate, and 
variability in quality of the LDCT image at a medium-sized community hospital has been 
described.96
Follow-up of Abnormal Results
In the section titled “Other Considerations,” the Task Force’s 2013 recommendation 
statement supports the establishment of protocols for follow-up of abnormal results such as 
the clinical practice guidelines in oncology for lung cancer screening by the National 
Comprehensive Care Network.59 In the NLST, an LDCT screening examination was 
considered positive for potential lung cancer if there were noncalcified pulmonary nodules 
with a long-axis diameter of 4 mm or more in the axial plane.97 Approximately 27% of 
initial screening examinations were positive.97 Several different groups have developed 
recommendations for the follow-up management of solid and subsolid nodules (subsolid 
nodules are common with peripheral adenocarcinoma).56–59 Many nodules are benign, but it 
may take 1 to 2 years to rule out cancer. The nodule size is one of the key decision 
parameters in the follow-up management algorithms. To reduce the number of false 
positives, increasing the minimum nodule size for positive results to 7 to 8 mm has been 
suggested.98 Research is ongoing to accurately estimate the probability of a lung nodule 
detected by LDCT screening being malignant.56,99,100
SMOKING CESSATION
Smoking prevention and cessation remain the fundamental strategies to drastically reduce 
the number of cases of lung cancer in the United States and elsewhere. Several studies 
conclusively show that smoking cessation lowers the risks for lung cancer among 
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smokers.34,35,101 However, the risk for lung cancer remains greater in former smokers than 
in lifetime nonsmokers.101,102
A small number of studies have been conducted to determine whether lung cancer screening 
with LDCT increases the chances of smoking cessation or changes perceptions about 
quitting.103–108 The limited available data seem to indicate that patients who receive LDCT 
screening, similarly to those who do not, have other factors that may better predict smoking 
cessation. For smokers, the factors associated with nicotine dependence at the time of the 
LDCT screening such as the number of cigarettes smoked per day and the time smoking the 
first cigarette in the morning, as well as other factors such as having 1 or more smoking-
related diseases (eg, emphysema, chronic pulmonary obstructive disease), are likely to be 
better predictors of quit attempts and smoking cessation than receiving LDCT screening. For 
former smokers, the time passed since they last smoked a cigarette and having 1 or more 
smoking-related diseases are likely to be better predictors of relapse than receiving LDCT 
screening.
Under “Other Considerations,” the 2013 Task Force recommendation statement indicates 
that lung cancer screening with LDCT should not be viewed as an alternative to tobacco 
cessation, and current smokers should be informed of their continued risk for lung cancer 
and be offered cessation treatments before referral.80 A potential area for future research 
might be whether the expanded use of lung cancer screening with LDCT in community 
practice will be associated with increased attention to smoking cessation messages given by 
health professionals; in 2010, only 48.3% of adult smokers had been advised by a health 
professional to quit.42 A smoking cessation message provided in a clear, strong, and 
personalized manner by a health professional increases abstinence by current smokers.109 
Former smokers, particularly those who have recently quit, may also potentially benefit 
from counseling that acknowledges the patient’s success and addresses any problems 
associated with cessation; emphasizes the importance of continued abstinence when they are 
referred for lung cancer screening with LDCT; and underscores the availability of support to 
resume abstinence if they relapse.109
Information is available for physicians and other health care practitioners on how to help 
their patients quit smoking. The US Public Health Services 2008 update of the Clinical 
Practice Guideline on Treating Tobacco Use and Dependence109 (hereafter referred to as the 
2008 Tobacco Use Guideline) provides guidance on intervening with smokers who want to 
quit or who have recently quit, and includes motivational messages for those not currently 
willing to make an attempt to quit. Effective treatments include individual, group, and 
telephone counseling, as well as 7 medications approved by the Food and Drug 
Administration. The effectiveness of the treatment increases with increasing intensity. 
Multiple counseling sessions are more effective than a brief single counseling session, and 
therapy combining counseling and medications is more effective than either component 
alone.
In addition to the proven strategies to encourage and support smoking cessation by health 
professionals, the 2008 Tobacco Use Guideline also points out that these strategies have not 
yet been fully implemented in health care settings, and that health care administrators, 
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insurers, and purchasers have an important role to play in helping to ensure that tobacco use 
is systematically assessed and treated with evidence-based strategies at every clinical 
encounter.109 Examples of potential interventions by the health care system include 
automated systems to identify smokers and an expanded insurance coverage of evidence-
based treatment for tobacco use (both medication and counseling). The 2008 Tobacco Use 
Guideline also acknowledges that additional research would be helpful for specific 
population groups (eg, smokers who have low socioeconomic status and limited formal 
education).109
Quitting smoking at any age improves health, and reduces the risk of lung cancer and other 
diseases.110,111 It is never too late to help patients to quit smoking. A Web site at the 
Centers for Disease Control and Prevention (http://www.cdc.gov/tobacco/campaign/tips/
quit-smoking/) includes tips from former smokers and resources for smokers who are ready 
to quit, and the National Cancer Institute (NCI) Web site (www.smokefree.gov) includes 
practical cessation information as well as information on how to sign up for SmokefreeTXT, 
which is a mobile text-messaging program for help to quit smoking. In addition, the NCI has 
a toll-free number that connects smokers to their state quitline, which smokers can call to 
talk to a coach for help to quit smoking: 1-800-QUIT-NOW (1-800-784-8669) or, for 
assistance in Spanish, 1-855-DÉJELO-YA (1-855-335-3569) (Box 2).
INFORMED AND SHARED DECISION-MAKING DISCUSSIONS
In the section “Other Considerations,” the 2013 Task Force recommendation statement 
indicates that the decision to begin screening should be made through a shared decision-
making process whereby patients and providers discuss the potential benefits, harms, and 
uncertainties of screening.80 In its “Clinician Fact Sheet,” the Task Force provides potential 
discussion points for 3 patient scenarios: patients who fit all screening criteria; patients who 
are outside the screening criteria; and patients who fit all screening criteria but have a 
significant comorbid condition.79
Other organizations recommending lung cancer screening with LDCT also have suggested 
an informed and shared decision-making process before referral for screening.81–86 Studies 
suggest that primary care providers need to tailor their approach to informed and shared 
decision making for each patient, for example by asking each patient for his or her input on 
the desired level of participation.112,113 Patients vary in their preference for participation in 
the decision-making process, with some preferring an active or collaborative role and others 
favoring a passive role. A patient’s preference may also change over time, and a mismatch 
between patients’ preferred and actual roles is common.112,113 A taxonomy has been 
proposed to categorize the harms that might occur during lung cancer screening with LDCT, 
including physical harms, psychological harms, financial strain, and opportunity costs.114
Higher-Risk Individuals
Tables 4 and 5 list selected examples of potential items for consideration during informed 
and shared decision-making discussions with patients, organized according to the Task 
Force’s previously suggested “5 As” framework: assess, advise, agree, assist, and 
arrange.115 One of the more important topics to be addressed is that lung cancer screening 
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with LDCT may involve a process over an extended period of time, rather than a single 
scan.83,116 For example, after a pulmonary nodule is identified, evaluation to determine 
whether the nodule is benign or malignant may require additional CT scans, more invasive 
procedures, additional cost, and follow-up for 1 to 2 years.116 The informed and shared 
decision-making discussion needs to occur before referral to LDCT screening, because 
many patients might assume that they have cancer when told that the LDCT scan has 
revealed a nodule.116 Patients with significant comorbid conditions should be informed that 
they may be at greater risk for harm with screening,79 and screening is not recommended if 
the comorbid conditions substantially limit life expectancy or the ability to undergo curative 
lung surgery.80
Lower-Risk Individuals
Primary care providers need to be prepared to answer questions about lung cancer screening 
with LDCT from individuals who do not meet the criteria for lung cancer screening with 
LDCT. Several examples include heavy smokers who are younger than the recommended 
age to begin screening, current or former smokers with fewer pack-years of smoking, 
individuals with other risk factors for lung cancer (eg, chronic obstructive lung disease), and 
healthy adults who have never smoked.79 In its “Clinical Fact Sheet” scenarios, the Task 
Force recommends that health providers inform patients in lower risk categories about the 
potential harms of screening and that there is not enough evidence to recommend screening 
for individuals at lower risk for lung cancer.79 The American Cancer Society also 
recommends informing individuals in lower risk categories that screening is not 
recommended at this time because there is too much uncertainty regarding the balance of 
benefits and harms (Box 3).82
HEALTH CARE CHANGES
Reimbursement for Grade A or B Preventive Services
The Patient Protection and Affordable Care Act requires most health insurance plans to 
cover preventive services at no additional cost to the patient if the Task Force grades the 
preventive service recommendation as A (strongly recommended) or B (recommended).117 
Both tobacco cessation (graded A) and lung cancer screening with LDCT (graded B) would 
qualify for insurance coverage at no additional cost.
Patient-Centered Medical Home
The patient-centered medical home is a model to improve the delivery of primary care by 
greater involvement of the patient in care plans, coordinated and comprehensive team-based 
care, improved patient access to care after hours and by e-mail and phone, and a 
commitment to quality improvement and population health management.118 In the context 
of lung cancer screening with LDCT, the primary care patient-centered medical home will 
remain important even if the primary care provider refers patients to a structured program 
that offers lung cancer screening and follow-up management. Several examples of potential 
activities for the primary care provider include identification of patients eligible for lung 
cancer screening with LDCT, informed and shared decision-making discussions with 
patients before referral, promotion of smoking cessation, management of comorbid 
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conditions that are not addressed by specialists, and eliminating barriers to timely 
care.119,120
Electronic Health Records
If electronic health records (EHRs) include information on patient age and pack-years of 
smoking, EHRs may be used to identify individuals who meet the eligibility criteria for lung 
cancer screening with LDCT. Computer algorithms may be designed to use with EHRs to 
provide patients with cellphone reminders about the need to schedule their annual lung 
cancer screening with LDCT and the importance of smoking cessation.121,122 An integrated 
system of EHRs may also facilitate the retrieval of information from multiple providers to 
evaluate the performance and quality of a lung cancer screening program with LDCT, notify 
the responsible clinicians about abnormal imaging results that need follow-up, and improve 
the early recognition of patients with lung cancer.121,122
Accountable Care Organizations
The Patient Protection and Affordable Care Act encourages groups of providers to 
collaborate, manage, and coordinate the care of patients through accountable care 
organizations (ACOs).117 ACOs that meet quality performance standards are eligible to 
receive payments for shared savings. Bekelman and colleagues123 have suggested that 
cancer specialists in larger, urban health care markets may want to develop Cancer Care 
Groups to provide guideline-concordant, patient-centered, coordinated care among cancer 
specialists and primary care providers. Activities related to lung cancer screening with 
LDCT would seem reasonable for ACOs to consider, especially if lung cancer screening 
with LDCT and follow-up is managed as part of a structured program with a 
multidisciplinary team.
SUMMARY
Annual LDCT screening for lung cancer cannot prevent lung cancer, but can reduce 
mortality from lung cancer in persons at high risk based on the age and smoking history of 
the individual. Lung cancer screening can supplement, but not replace, efforts to address the 
primary prevention of lung cancer through the control of tobacco and other known risk 
factors associated with lung cancer. Considerations for primary care providers may include 
the resources available in their communities for lung cancer screening with LDCT and for 
smoking cessation, and the key points that need to be addressed in the informed and shared 
decision-making discussions with patients. Lung cancer screening with LDCT is a rapidly 
evolving area. Examples of upcoming areas of potential importance may include the 
following: decisions from Centers for Medicare and Medicaid Services about reimbursement 
and billing codes; ACR recommendations on quality control and reporting of LDCT 
findings; results from additional analyses of the NLST data; results from European studies, 
especially on the use of volume-doubling time to evaluate whether pulmonary nodule sizes 
have changed over time; and whether a national consensus can be developed with standard 
algorithms for patient management.
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• The US Preventive Services Task Force recommends annual low-dose 
computed tomography (LDCT) screening for lung cancer for persons at high 
risk for lung cancer, based on the age and smoking history of the individual.
• Lung cancer screening with LDCT does not prevent lung cancer, nor does it 
eliminate the need to extend smoking cessation referral and support to current 
smokers screened for lung cancer.
• Several organizations have recommended that lung cancer screening with LDCT 
be conducted as part of structured, high-volume, high-quality programs by a 
multidisciplinary team skilled in the evaluation and treatment of lung cancer.
• It is important for primary care providers to know the resources available in 
their communities for lung cancer screening with LDCT and smoking cessation, 
and the key points to be communicated to patients for informed and shared 
decision-making discussion about lung cancer screening.
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Structured lung cancer screening
Formal program
Access to a multidisciplinary clinical team and clinical resources to provide diagnosis, 
follow-up treatment, and long-term patient management related to lung screening
Patient eligibility criteria consistent with Task Force recommendations
Informed and shared decision-making discussions before initial screening
Smoking cessation program
American College of Radiology certification in computed tomography
Staff and resources for data collection to monitor program quality
Participation in American College of Radiology data registry program
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Resources for smoking cessation
Resources for Patients




Tips from former smokers
http://www.cdc.gov/tobacco/campaign/tips/index.html
Resources for Clinicians and Other Health Providers
Treating tobacco use and dependence
http://www.ahrq.gov/professionals/clinicians-providers/guidelines-
recommendations/tobacco/clinicians/presentations/2008update-overview/index.html
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Resources for patients about lung cancer screening
American Cancer Society. Patient Page. Testing for lung cancer in people at high risk. 
CA Cancer J Clin 2013;63(2):118–9. http://www.cancer.org/healthy/
informationforhealthcareprofessionals/acsguidelines/lungcancerscreeningguidelines/
index
American Lung Association. Lung cancer CT screening for early detection. One pager. 
http://www.lung.org/lung-disease/lung-cancer/lung-cancer-screening-guidelines/lung-
cancer-onepager.pdf
American Lung Association. Provides guidance on lung cancer screening. Full Report. 
Appendix I. American Lung Association Toolkit. Making an individual decision to be 
screened. http://www.lung.org/lung-disease/lung-cancer/lung-cancer-screening-
guidelines/
National Cancer Institute. Patient and physician guide: National Lung Screening Trial. 
http://www.cancer.gov/newscenter/qa/2002/NLSTstudyGuidePatientsPhysicians
National Cancer Institute. Lung cancer screening (PDQ). Patient version. http://
www.cancer.gov/cancertopics/pdq/screening/lung/Patient/page1/AllPages
National Comprehensive Cancer Network. NCCN guidelines for patients. Lung cancer 
screening. Version 1. 2014. http://www.nccn.org/
National Framework for Excellence in Lung Cancer Screening and Continuum of Care. 
Lung Cancer Alliance. http://www.lungcanceralliance.org
US Preventive Services Task Force. Consumer fact sheet. Understanding Task Force 
recommendations. Screening for lung cancer. http://
www.uspreventiveservicestaskforce.org/adultrec.htm
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Table 1
Selected benefits and harms of lung cancer screening reported by the National Lung Screening Trial for all 3 
rounds, comparing low-dose computed tomography (LDCT) with chest radiographya
LDCT Chest Radiography
Participants
  No. of participants 26,722 26,732
  Adherence to 3 rounds of screening 95% 93%
  Person-years 144,103 143,368
Benefits
  Lung cancer deaths 356 443
  Rate of death from lung cancer per 100,000 person-years 247 309
  Relative reduction in mortality from lung cancer with LDCT 62/309 = 20% —
Risk of Harms
  Percentage of tests classified as positive 24.2% 6.9%
  Percent of positive results that were false positives 96.4% 94.5%
  Rate of at least 1 complication after the most invasive screening related diagnostic procedureb 1.4% 1.6%
  Percentage of positive screening tests associated with a major complication from invasive screening 
related diagnostic proceduresb when:
    Lung cancer not diagnosed 0.06% 0.02%
    Lung cancer diagnosed 11.2% 8.2%
  Deaths within 60 d after the most invasive screening-related diagnostic procedureb 16 10
a
The NLST conducted screening from August 2002 to September 2007, and followed up the participants through December 31, 2009. Analysis of 
the number of deaths from lung cancer includes deaths that occurred from the date of randomization through January 15, 2009 (6.5 years’ follow-
up).
b
Invasive procedures include mediastinoscopy or mediastinotomy, thoracoscopy, or thoracotomy.
Data from National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed 
tomographic screening. N Engl J Med 2011; 365(5):395–409.
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Table 2
Selected benefits and harms of lung cancer screening with annual low-dose computed tomography (LDCT) 
screening reported by the Cancer Intervention and Surveillance Modeling Network
Screening Scenario
  Scenario identification code A55-80-30-15
  Frequency of screening Annual
  Smoking requirement Ever-smokers with at least 30 pack-years, and no more than 15 y since quitting for 
former smokers
  Start screening at age 55 y
  End screening at age 80 y
Study Cohort
  Cohort size 100,000 persons
  Cohort age range 45–90 y
  Proportion of cohort that receive screeninga 19%
Benefits
  Lung cancer detected at an early stage (stage I or II) 50.5%
  Lung cancer mortality reductionb 14.0%
  Lung cancer deaths averted 521
Harms
  Total no. of screenings with LDCT 286,813
  No. of overdiagnosed casesc 190
  Overdiagnosis, % of all casesc 3.7%
  Overdiagnosis, % of screening detected casesc 9.9%
  No. of lung cancer deaths related to radiation exposure 24
  LDCT scans per lung cancer death averted 550
a
The Cancer Intervention and Surveillance Modeling Network (CISNET) assumed that only eligible persons (19%) in the cohort were screened, 
whereas the NLST screened almost all enrolled persons in the LDCT arm.
b
CISNET analysis of the number of deaths from lung cancer included 7.5 years of follow-up compared with the 6.5 years of follow-up reported in 
the National Lung Screening Trial.
c
Overdiagnosis refers to slow-growing or indolent lung cancers.
Data from de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative 
modeling study for the US Preventive Services Task Force. Ann Intern Med 2013; http://dx.doi.org/10.7326/M13-2316.
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Table 3
Lung cancer screening recommendations
Organization Groups Eligible for Screening Year
American Association for Thoracic 
Surgery81
1 Age 55–79 y with ≥30 pack-year smoking history
2 Long-term lung cancer survivors who have completed 4 y of surveillance 
without recurrence, and who can tolerate lung cancer treatment to detect second 
primary lung cancer until the age of 79 y
3 Age 50–79 y with a 20 pack-year smoking history and additional comorbidity 
that produces a cumulative risk of developing lung cancer ≥5% in 5 y
2012
American Cancer Society82 Age 55–74 y with ≥30 pack-year smoking history, either currently smoking or have quit 
within the past 15 y, and who are in relatively good health
2013
American College of Chest Physicians83 Age 55–74 y with ≥30 pack-year smoking history and either continue to smoke or have 
quit within the past 15 y
2013
American College of Chest Physicians 
and American Society of Clinical 
Oncology84
Age 55–74 y with ≥30 pack-year smoking history and either continue to smoke or have 
quit within the past 15 y
2012
American Lung Association85 Age 55–74 y with ≥30 pack-year smoking history and no history of lung cancer 2012
National Comprehensive Cancer 
Network86
1 Age 55–74 y with ≥30 pack-year smoking history and smoking cessation <15 y
2 Age ≥50 y and ≥20 pack-year smoking history and 1 additional risk factor 
(other than secondhand smoke)a
2012
US Preventive Services Task Force79,80 Age 55–80 y with ≥30 pack-year smoking history and smoking cessation <15 y 2013
a
Additional risk factors include cancer history, lung disease history, family history of lung cancer, radon exposure, occupational exposure, and 
history of chronic obstructive pulmonary disease or pulmonary fibrosis. Cancers with increased risk of developing new primary lung cancer include 
survivors of lung cancer, lymphomas, cancer of the head and neck, and smoking-related cancers. Occupational exposures identified as carcinogens 
targeting the lungs include silica, cadmium, asbestos, arsenic, beryllium, chromium(VI), diesel fumes, and nickel.













Richards et al. Page 28
Table 4
Selected examples of items to be considered in informed and shared decision-making discussions about 
screening for cancer with low-dose computed tomography (LDCT)
Steps Components
Assess Availability: Is an organized, high-volume, high-quality lung cancer screening program available with a multidisciplinary team 
skilled in lung cancer evaluation and treatment?
Eligibility: Does the patient meet lung screening eligibility criteria?
Time: Is time available for informed and shared decision-making discussions with the patient?
Knowledge: What is the patient’s level of knowledge about lung cancer and lung cancer screening? What is the patient’s literacy 
level?
Preferences: Does the patient prefer an active, shared, or passive role in the decision-making discussions?
Advise Purpose: Annual LDCT screening can detect lung cancer at an early stage in asymptomatic high-risk individuals. Lung cancer 
screening should be thought of as a process rather than a single test
Smoking cessation: Current smokers should STOP SMOKING. Screening should not be viewed as an alternative to smoking 
cessation. Avoiding cigarettes can lower the risk of lung cancer, emphysema, heart disease, and vascular disease
Benefits: LDCT may reduce the risk of dying from lung cancer in heavy smokers. For individuals meeting the minimum eligibility 
requirements, benefits of screening are greater in individuals who have been heavier smokers
Harms: There is a significant chance of false alarms (false positives) with LDCT screening. Repeat testing over 1–2 y may be 
required to evaluate if a screen detected abnormality increases in size. In some cases, an invasive procedure (eg, needle biopsy, 
bronchoscopy, or thoracotomy) is needed to determine whether the abnormality is lung cancer. Invasive diagnostic procedures may 
result in major complications, and are more common in patients who have lung cancer. Death within 60 d has occurred after an 
invasive diagnostic procedure, but is rare
Radiation exposure: Provide estimated radiation exposure for your location with 1 LDCT lung screening scan, and the cumulative 
lifetime total radiation with repeat annual screening
Patient costs: How much does the patient need to pay for a scan? What is the cost of patient copayments for follow-up consultations 
and procedures?
Scientific uncertainties: Negative screening results do not absolutely rule out the chance for lung cancer incidence. LDCT will not 
detect all lung cancers or all lung cancers early, and not all patients who have a lung cancer detected by LDCT will avoid death from 
lung cancer
Research: How can screened individuals donate images and biospecimens to advance research in the prevention, diagnosis, and 
treatment of lung cancer?
Alternatives: LDCT is the only screening test shown to lower the chances of dying of lung cancer. Chest radiography should not be 
used for lung cancer screening
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Table 5
Informed and shared decision-making discussions
Steps Components
Agree Provider needs to help individuals clarify their preferences and willingness to be screened
Decide to screen with LDCT every year Individual assigns higher value to potential benefits than to potential harms
Decide against LDCT screening: Individual assigns higher value to potential harms than to the potential benefits
Assist Costs: Help individuals determine if they have to pay for the initial LDCT scan and how much
Referral: Provider identifies screening facilities with appropriate expertise, refers individual for screening, and informs individual 
how to schedule the screening test or that the screening clinic will contact the individual
Arrange Smoking cessation: Provider should provide smoking cessation or refer current smokers to smoking cessation programs
Results: How and when will the LDCT results be communicated to patients?
Follow-up When will the informed-shared decision-making process about LDCT screening be revisited in the future?
Update Preferences and decisions Assess any change over time in patient preferences and decisions before referral for the next annual 
LDCT screening
Document Documentation Clearly document the informed and shared decision-making process and decisions to safeguard against potential 
medicolegal consequences (eg, if a case of lung cancer is detected before a decision has been made about lung cancer screening; 
or if the individual has major complications from lung cancer screening). Documentation may potentially need to cover more than 
1 visit (eg, initial discussion with patient, follow-up discussions between patient and support staff, and educational materials 
provided to patient)
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